|Author||: Philippe Auby|
|Publisher||: Woodhead Publishing|
|Release Date||: 2019-09-15|
|ISBN 10||: 0081006179|
|Pages||: 218 pages|
Clinical Research in Paediatric Psychopharmacology: An Overview of the Ethical, Scientific and Regulatory Aspects provides a practical guide and overview of the ethical, scientific and regulatory aspects of clinical research in pediatric psychopharmacology, also discussing practical points to consider when developing clinical research in this field. The book is ideal for professionals involved in clinical research in pediatric psychopharmacology, i.e., including, but not limited to pediatricians, health care professionals, researchers, investigators, pharmaceutical company personals and potentially ethics committee members. Topics discussed include the role of patient organization and advocacy groups in research, the role of families and patients: ‘should I involve my kid in clinical research, and historical, ethical, regulatory, clinical, scientific, intercultural and practical aspects of clinical research in child and adolescent psychopharmacology. Covers both theoretical and practical aspects of clinical research in paediatric psychopharmacology Approaches the topic from different angles from the regulatory framework to the patient perspective Discusses ethical and safety considerations for research in paediatric psychopharmacology Offers future perspective for paediatric development
When the first edition of Pediatric Psychopharmacology published in 2002, it filled a void in child and adolescent psychiatry and quickly establishing itself as the definitive text-reference in pediatric psychopharmacology. While numerous short, clinically focused paperbacks have been published since then, no competitors with the scholarly breadth, depth, and luster of this volume have emerged. In the second edition, Christopher Kratochvil, MD, a highly respected expert in pediatric psychopharmacology, joins the outstanding editorial team led by Dr. Martin and Dr. Scahill. In the new edition, the editors streamline the flow of information to reflect the growth in scientific data since the first edition appeared. The overall structure of the book remains the same, with major sections on underlying biology; somatic interventions; assessment and treatment; and special considerations.
|Author||: Molly McVoy,Robert L. Findling|
|Publisher||: American Psychiatric Pub|
|Release Date||: 2017-03-15|
|ISBN 10||: 1615371265|
|Pages||: 545 pages|
The new, third edition of the Clinical Manual of Child and Adolescent Psychopharmacology has been thoroughly revised, yet its mission remains the same: to keep clinicians up-to-date on the latest research so that they can provide state-of-the-art care to their young patients. To this end, the book describes and explores those elements that are specific to pediatric psychopharmacology; this defines and positions the volume at the nexus of child and adolescent psychiatry, pediatrics, and pharmacology. A stellar roster of contributors addresses new treatments for youths with disruptive behavior disorders, mood disorders, anxiety disorders, pervasive developmental disorders, and psychotic illnesses and tackles some of the most important emerging issues in the field. For example, advances in understanding the long-term treatment effects of medications in pediatric populations are thoroughly reviewed, including not only maintenance studies that consider the durability of efficacy but also clinical trials of greater duration designed to specifically evaluate long-term safety. In addition, recent studies of combination therapies are examined, helping clinicians better understand how to treat the complicated patients that arrive every day at a prescribing clinician's office. Finally, because research designs now include a broader base of patient populations to make the data more applicable to everyday clinical practice, the book focuses on head-to-head studies with multiple active comparators. The book offers clinicians comprehensive, accessible information and boasts a multitude of helpful features: The book is organized by diagnosis instead of agent class. This makes it a true clinical desktop reference that allows clinicians to quickly and efficiently search treatment options and the evidence base on a case-by-case basis. DSM-5 criteria and information on comorbidities are also included. The American Academy of Child and Adolescent Psychiatry Practice Parameters are integrated into the discussion, where applicable, in support of standard of care. The book has been updated to include the latest research at the time of publication. A new chapter has been added to address eating disorders, an area where psychopharmacological research that may apply to children and adolescents is now being pursued. Useful features to help the reader understand and retain the material include clinical summary points, easy to read tables, and current and carefully vetted references. The Clinical Manual of Child and Adolescent Psychopharmacology, Third Edition, is an indispensable guide to the substantive research that has been done in nearly every area of pediatric psychopharmacology, as well as the major improvements that have been made to the evidence-based practice of treating youths with psychiatric illness.
Pediatric Psychopharmacology: Principles and Practice is an authoritative and comprehensive text on the use of medication in the treatment of children and adolescents with serious neuropsychiatric disorders. This benchmark volume consists of 56 chapters written by internationally recognized leaders, and is divided into four interrelated sections. The first, Biological Bases of Pediatric Psychopharmacology, reviews key principles of neurobiology and the major psychiatric illnesses of childhood from a perspective rooted in developmental psychopathology. The second, Somatic Interventions, presents the major classes of psychiatric drugs, as well as complementary and alternative somatic interventions, such as electroconvulsive therapy (ECT), transcranial magnetic stimulation (rTMS), and naturopathic approaches. The third and longest section, Assessment and Treatment,starts with clinical assessment, diagnostic evaluation, and comprehensive treatment planning, and goes on to cover the evidence-based analysis of drug treatments for the major disorders. Special populations (such as children with comorbid mental retardation, substance abuse or medical illness) are specifically discussed, and the coordination of their treatment with non-somatic therapies is explicitly addressed. The final section, Epidemiologic, Research, and Methodological Considerations, deals with broad population-relevant topics such as regulation and policy, pharmacoepidemiology, and the critical importance of sound ethical principles for clinical investigation. The book concludes with an appendix on generic and commercial drug name equivalencies, preparations, and available dosages. This timely text is intended for child and adolescent psychiatrists, general and developmental pediatricians, family practitioners, general psychiatrists, and other mental health professionals who work with children and adolescents.
|Author||: Thomas H. Ollendick,Susan W. White,Bradley A. White|
|Publisher||: Oxford Library of Psychology|
|Release Date||: 2018-12-07|
|ISBN 10||: 0190634847|
|Pages||: 816 pages|
At the founding in 1896 of the first psychological clinic dedicated to children and adolescents, the study of the psychological treatment of young people lagged behind that of adults, and the basic psychopathology underlying mental disorders in this population was largely ignored. Since those early days, the field has evolved steadily and, in recent years, exponentially. The Oxford Handbook of Clinical Child and Adolescent Psychology is a state-of-the-science volume providing comprehensive coverage of the psychological problems and disorders of childhood. International in scope and penned by the discipline's most eminent scientists and practitioners, the handbook begins with a section on conceptual and empirical issues, followed by exceptional content on specific psychiatric disorders such as intellectual disability, externalizing and internalizing disorders, communication disorders, schizophrenia and bipolar disorder, personality disorders, and many more. The third section offers chapters on special problems in childhood and adolescence, including divorce, the incarceration of parents, suicide and non-suicidal self-injury, bullying, and medical illness. A fourth section covers delivery of clinical services in diverse settings, such as schools and prisons, and the handbook concludes with several chapters on emerging trends and future directions for the field. Conceptually rich and evidence-based, this handbook is an essential resource for students, practitioners, and researchers, providing a cutting-edge compendium of the latest theoretical and empirical developments by leaders of the discipline.
Confidently prescribe, monitor, and manage medications for childhood mental health disorders. This game-changing resource from the American Academy of Pediatrics (AAP) arms you with a unique strategic approach - plus practice-tested, condition-specific treatment recommendations. Obtain clear guidance on dosing, monitoring, and potential adverse reactions of psychotropic medications for treatment of common psychiatric disorders and mental health or behavioral problems in children and adolescents. Free bonus digital tool! Get instant answers on specific conditions and medications from your desktop or mobile device! Evidence-based conceptual framework A clear, straightforward methodology - based on current research and clinical experience - defines discrete levels of psychotropic agents and spells out level-specific roles and responsibilities. Group 1: Medications FDA-approved for youth for ADHD, anxiety, and depression - disorders for which pediatric primary care providers commonly initiate treatment and assume prescribing and monitoring responsibilities. Administration and management information for each drug agent includes: Rationale for use Evidence supporting efficacy and safety Initial dosing and subsequent adjustments Measuring therapeutic success When to consult or refer Group 2: Medications FDA-approved for youth, typically prescribed by specialists but often monitored in the primary care setting antipsychotics, mood stabilizers, antidepressants, anxiolytics, and sleep aids. To support primary care clinician's collaborative role, usage rationales, efficacy data, and adverse effect profiles are specified for all of these agents. Group 3: Medications not FDA-approved for youth that primary care clinicians will likely encounter. To support primary care clinician's collaborative role, efficacy data and adverse effect profiles are specified for these agents. Proven, practice-focused guidance Hands-on help spanning the therapeutic process: Assessing for common disorders Assessing for psychiatric comorbidities Identifying medication needs Informed consent Monitoring patient progress Managing side effects Managing multiple medications Stopping or changing medications
|Author||: Mark A. Riddle,Rebecca A. Baum,Susan dosReis,Emily Frosch,Jane Meschan Foy,Cori Green,Lynne C. Huffman,David Pruitt,Gloria M. Reeves,Lawrence S. Wissow|
|Release Date||: 2018-11-15|
|ISBN 10||: 9781610021999|
|Pages||: 250 pages|
Completely updated and revised, the second edition provides primary care physicians with practice-tested, condition-specific treatment recommendations for various childhood mental disorders. Obtain clear guidance on dosing, monitoring, and potential adverse reactions of psychotropic medications for treatment of common psychiatric disorders and mental health or behavioral problems in children and adolescents. This simple, systematic approach defines discrete levels of psychotropics and spells out group-specific roles and responsibilities in accord with AAP policies. Plus, an included digital tool offers instant access to authoritative answers on specific conditions and medications. TOPICS INCLUDE Conceptual framework for prescribing psychotropic drugs Medications for specific diagnoses: ADHD, Anxiety, and Depression US Food and Drug Administration-Approved antipsychotics and mood stabilizers and all other medications What to do when treatment is unsuccessful
|Author||: William Klykylo,Rick Bowers,Julia Jackson,Christina Weston|
|Publisher||: Lippincott Williams & Wilkins|
|Release Date||: 2013-09-24|
|ISBN 10||: 1469830795|
|Pages||: 416 pages|
The ideal quick reference for the busy mental health clinician seeing younger patients, the Fifth Edition of Green’s Child and Adolescent Clinical Psychopathology has been fully revised by a new team of authors active in clinical practice and resident education. A trusted reference in the field, Green’s continues to provide practical and balanced information on the full range of medications used to treat mental health disorders in children and adolescents.
|Author||: Philippe Auby|
|Release Date||: 2015-01-31|
|ISBN 10||: 9781908818607|
|Pages||: 220 pages|
Clinical research in pediatric psychopharmacology covers ethical, regulatory, clinical, scientific, intercultural and practical aspects of clinical research in child and adolescent psychopharmacology. Clinical Research in Paediatric Psychopharmacology: A Practical Guide is written and organized with the aim of being a practical guide, providing both an overview of clinical research in pediatric psychopharmacology and practical points to consider when developing clinical research in this field. Covers both theoretical and practical aspects Includes the regulatory framework and the patient perspective Priovides real insight rather than tips